| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
BAY-1797 targets the purinergic P2X₄ receptor, a ligand-gated ion channel activated by ATP. It acts as a selective antagonist with an IC₅₀ of 211 nM for the human receptor. It is selective for P2X₄ over P2X₁, P2X₉, and P2X₇ receptors (IC₅₀s = >50, 8.3, and 10.6 µM).
|
|---|---|
| ln Vitro |
BAY-1797 exhibits inhibitory effect against the dopamine transporter (DAT, IC50 2.17 μM), but no discernible activity against phosphodiesterase II and hERG [1].
In vitro, BAY-1797 inhibits human, mouse, and rat P2X4 in 1321N1 cells with IC₅₀ values of 108 nM, 112 nM, and 233 nM, respectively. It exhibits inhibitory effect against the dopamine transporter (DAT, IC₅₀ 2.17 µM), but no discernible activity against phosphodiesterase II and hERG. |
| ln Vivo |
In an animal model of inflammatory pain in mice using the complete Freund's adjuvant (CFA) model, BAY-1797 (12.5–50 mg/kg; face) dramatically increases PGE2 in paws [1]. Within 24 and 48 hours following CFA injection, ipsilateral paw burden is significantly reduced by BAY-1797 (50 mg/kg; once daily, many times on the table) [1]. AUCnorm, Vss, and t1/2 were 1.06 kg h/L, 3.67 L, and 1.06 kg h/L, respectively, according to BAY-1797 therapy.
In vivo, BAY-1797 has demonstrated anti-inflammatory and anti-nociceptive effects in a mouse complete Freund's adjuvant (CFA) inflammatory pain model. In this model, BAY-1797 (12.5–50 mg/kg; oral) dramatically increases PGE2 in paws. Within 24 and 48 hours following CFA injection, ipsilateral paw burden is significantly reduced by BAY-1797 (50 mg/kg). |
| Enzyme Assay |
In vitro assays for BAY-1797 typically involve measuring its inhibition of P2X4 receptor activity. The compound's inhibitory effect is assessed in calcium influx-based assays using cells expressing the P2X4 receptor. IC₅₀ values for human, mouse, and rat P2X4 are determined from dose-response curves. Selectivity is confirmed by testing against a panel of other P2X ion channels and related targets.
|
| Cell Assay |
For in vitro cell-based assays, cells expressing the P2X4 receptor (e.g., 1321N1 cells) are cultured and treated with BAY-1797 at various concentrations. Receptor antagonism is confirmed by its ability to block ATP-induced calcium influx, measured using fluorescent calcium indicators. Cell viability is assessed by standard assays such as MTT.
|
| Animal Protocol |
Animal/Disease Models: Female adult C57BL/6N mouse (CFA inflammatory pain model) [1]
Doses: 12.5, 25, 50 mg /kg Route of Administration: po; /kg and 2.64 hrs (hrs (hours)) [1]. Experimental Results: PGE2 concentration diminished in a dose-dependent manner in inflamed paws. Animal/Disease Models: Rat male Wistar[1] Doses: 1 mg/kg Route of Administration: intravenous (iv) (iv)injection (pharmacokinetic/PK/PK analysis) Experimental Results: AUCnorm, Vss and t1/2 were 1.06 kg·h/L, 3.67 L/ kg and 2.64 hrs (hrs (hours)). In vivo animal studies with BAY-1797 are conducted in models of inflammatory pain. Female adult C57BL/6N mice are used in the CFA inflammatory pain model. BAY-1797 is administered orally at doses of 12.5, 25, and 50 mg/kg. Efficacy is measured by reduction in ipsilateral paw burden and PGE2 concentration in inflamed paws. Pharmacokinetic analysis is performed in rat models. |
| ADME/Pharmacokinetics |
BAY-1797 (CAS: 2055602-83-8) has a molecular weight of 416.88 g/mol and a molecular formula of C₂₀H₁₇ClN₂O₄S. Appearance: Light yellow to yellow solid powder. LogP: 3.9. Solubility: Soluble in DMSO (up to 25 mg/ml). Storage: -20°C.
|
| Toxicity/Toxicokinetics |
BAY-1797 is a research compound and is not approved for human therapeutic use. In preclinical studies, it has shown a manageable safety profile. As a selective P2X4 antagonist, it is expected to have a targeted mechanism of action, which may reduce off-target effects. Standard laboratory safety precautions should be followed when handling the compound.
|
| References | |
| Additional Infomation |
BAY-1797 is a highly potent, orally bioavailable, and specific P2X4 antagonist with an IC₅₀ of 211 nM against human P2X4. It displays anti-nociceptive and anti-inflammatory effects. The compound has the CAS number 2055602-83-8. It is not FDA-approved and is intended for research use only.
|
| Molecular Formula |
C20H17CLN2O4S
|
|---|---|
| Molecular Weight |
416.877982854843
|
| Exact Mass |
416.059
|
| CAS # |
2055602-83-8
|
| PubChem CID |
124125214
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
3.9
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
28
|
| Complexity |
618
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC1=CC=CC(=C1)OC1C=CC(=CC=1S(N)(=O)=O)NC(CC1C=CC=CC=1)=O
|
| InChi Key |
CSJYMAFXYMYNCK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H17ClN2O4S/c21-15-7-4-8-17(12-15)27-18-10-9-16(13-19(18)28(22,25)26)23-20(24)11-14-5-2-1-3-6-14/h1-10,12-13H,11H2,(H,23,24)(H2,22,25,26)
|
| Chemical Name |
N‑[4-(3-Chlorophenoxy)-3-sulfamoylphenyl]-2-phenylacetamide
|
| Synonyms |
BAY-1797 BAY 1797 BAY1797
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~599.69 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.99 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.99 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.99 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3988 mL | 11.9939 mL | 23.9877 mL | |
| 5 mM | 0.4798 mL | 2.3988 mL | 4.7975 mL | |
| 10 mM | 0.2399 mL | 1.1994 mL | 2.3988 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
